Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
68°
Clear
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
Photos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Best of 2023
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Immuneering Corp Cl A
(NQ:
IMRX
)
1.070
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Immuneering Corp Cl A
< Previous
1
2
3
4
5
Next >
Why Shares of Immuneering Jumped This Week
March 24, 2023
Immuneering is ready to share information regarding its lead therapy.
Via
The Motley Fool
Immuneering to Present Data on Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2023
March 14, 2023
From
Immuneering Corporation
Via
GlobeNewswire
Top 5 Health Care Stocks That Are Ticking Portfolio Bombs
March 14, 2023
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies.
Via
Benzinga
Looking Into Immuneering's Return On Capital Employed
March 09, 2023
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
March 08, 2023
Via
Benzinga
Immuneering Earnings Preview
March 03, 2023
Via
Benzinga
Immuneering's Return On Capital Employed Insights
December 20, 2022
Via
Benzinga
Immuneering Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates
March 06, 2023
From
Immuneering Corporation
Via
GlobeNewswire
Immuneering Presents Preclinical Data with Lead Program IMM-1-104 Supporting Universal-RAS Activity
March 05, 2023
From
Immuneering Corporation
Via
GlobeNewswire
Immuneering Announces Participation in March Investor Conferences
February 28, 2023
From
Immuneering Corporation
Via
GlobeNewswire
Immuneering to Report Fourth Quarter and Full Year 2022 Financial Results and Business Updates
February 27, 2023
Management to host conference call on Monday, March 6 at 4:30 p.m. ET
From
Immuneering Corporation
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For February 3, 2023
February 03, 2023
Via
Benzinga
Immuneering To Present at Guggenheim 2023 Oncology Conference
January 31, 2023
From
Immuneering Corporation
Via
GlobeNewswire
Immuneering Announces First Patient Dosed in its Phase 1/2a Clinical Trial of IMM-1-104 in Advanced Solid Tumors with RAS Mutations
November 28, 2022
From
Immuneering Corporation
Via
GlobeNewswire
Immuneering Presents Promising Preclinical Data on its Second Program IMM-6-415 at the 37th Annual Meeting of SITC
November 10, 2022
From
Immuneering Corporation
Via
GlobeNewswire
Immuneering Reports Third Quarter 2022 Financial Results and Recent Business Highlights
November 10, 2022
From
Immuneering Corporation
Via
GlobeNewswire
Immuneering Announces Participation in November Investor Conferences
November 03, 2022
From
Immuneering Corporation
Via
GlobeNewswire
Immuneering Appoints Leah R. Neufeld as Chief People Officer
October 20, 2022
From
Immuneering Corporation
Via
GlobeNewswire
Immuneering To Present Poster on IMM-6-415 at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
October 05, 2022
From
Immuneering Corporation
Via
GlobeNewswire
Why F45 Training Shares Climbed 41%; Here Are 84 Biggest Movers From Friday
October 03, 2022
Gainers FingerMotion, Inc. (NASDAQ: FNGR) gained 82.2% to close at $3.37.
Via
Benzinga
Why Carnival Shares Are Trading Lower By 19%, Here Are 49 Stocks Moving In Friday's Mid-Day Session
September 30, 2022
Gainers
Via
Benzinga
Micron, Charles River Laboratories And Some Other Big Stocks Moving Higher On Friday
September 30, 2022
U.S. stocks traded slightly higher, with the Nasdaq Composite gaining more than 80 points on Friday. Here are some big stocks recording gains in today’s session.
Via
Benzinga
Immuneering Announces FDA Clearance of IND Application for Phase 1/2a Clinical Trial of IMM-1-104 to Treat Advanced Solid Tumors with RAS Mutations
September 30, 2022
Initiation of Phase 1/2a Clinical Trial Expected to Occur in Q4 2022
From
Immuneering Corporation
Via
GlobeNewswire
Why Avenue Therapeutics Shares Surged Around 106%; Here Are 87 Biggest Movers From Yesterday
September 23, 2022
Gainers
Via
Benzinga
Why Comera Life Sciences Shares Jumped 101%; Here Are 74 Biggest Movers From Yesterday
September 14, 2022
Gainers Akero Therapeutics, Inc. (NASDAQ: AKRO) shares jumped 136.8% to settle at $29.05 on Tuesday after the company's Phase 2b HARMONY study met its primary endpoint for both the 50mg and 28mg EFX...
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
September 06, 2022
Gainers Metacrine (NASDAQ:MTCR) shares rose 13.8% to $0.54 during Tuesday's after-market session. This security traded at a volume of 3.0 million shares come close, making up 948.6% of its average...
Via
Benzinga
Recap Of Friday's Biotech Catalysts - End Of the Day Summary
September 02, 2022
Via
Benzinga
Immuneering Shares Climb After Pursuing FDA Nod For RAS Mutant Tumor Study
September 02, 2022
Immuneering (NASDAQ: IMRX) submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for its product candidate IMM-1-104 in development for the treatment of...
Via
Benzinga
Why Snap Shares Jumped 7%; Here Are 75 Biggest Movers From Yesterday
September 02, 2022
Gainers
Via
Benzinga
Tesla, Twitter And 76 Biggest Movers From Friday
July 11, 2022
Gainers Seritage Growth Properties (NYSE: SRG) shares surged 80.3% to settle at $10.96 after the company appointed Adam Metz as Chairman. Preliminary proxy materials also indicated the board...
Via
Benzinga
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.